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Pulmonary tuberculosis (TB), which is caused by Mycobacterium tuberculosis (Mtb),
remains a global pandemic, despite the widespread use of the parenteral live
attenuated Bacillus Calmette–Guérin (BCG) vaccine during the past decades. Mucosal
administration of next generation TB vaccines has great potential, but developing a
safe and efficacious mucosal vaccine is challenging. Hence, understanding the in vivo
biodistribution and pharmacokinetics of mucosal vaccines is essential for shaping the
desired immune response and for optimal spatiotemporal targeting of the appropriate
effector cells in the lungs. A subunit vaccine consisting of the fusion antigen H56
(Ag85B-ESAT-6-Rv2660) and the liposome-based cationic adjuvant formulation (CAF01)
confers efficient protection in preclinical animal models. In this study, we devise a novel
immunization strategy for the H56/CAF01 vaccine, which comply with the intrapulmonary
(i.pulmon.) route of immunization. We also describe a novel dual-isotope (111In/67Ga)
radiolabeling approach, which enables simultaneous non-invasive and longitudinal
SPECT/CT imaging and quantification of H56 and CAF01 upon parenteral prime and/or
i.pulmon. boost immunization. Our results demonstrate that the vaccine is distributed
evenly in the lungs, and there are pronounced differences in the pharmacokinetics of
H56 and CAF01.We provide convincing evidence that the H56/CAF01 vaccine is not only
well-tolerated when administered to the respiratory tract, but it also induces strong lung
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mucosal and systemic IgA and polyfunctional Th1 and Th17 responses after parenteral
prime and i.pulmon. boost immunization. The study furthermore evaluate the application
of SPECT/CT imaging for the investigation of vaccine biodistribution after parenteral and
i.pulmon. immunization of mice.
Keywords: H56/CAF01 vaccine, SPECT/CT imaging, dual-isotope 111In/67Ga, pulmonary immunization, T cells,
mucosal immunity, nanomedicine, drug delivery
INTRODUCTION
Mycobacterium tuberculosis (Mtb), which is causing pulmonary
tuberculosis (TB), has infected humans for thousands of years
and it is estimated that about one third of the global population
is latently infected with TB, which continues to infect 10
million and kill more than 1.5 million people every year (1–
3). Increased multi-drug resistance and extensive drug-resistance
against existing antibiotics, and the very slow progress in
developing new types of antibiotics might result in even poorer
prognosis in the future if novel solutions to fight TB are not
found. To date, the only licensed TB vaccine remains the live
attenuated Bacillus Calmette–Guérin (BCG) vaccine developed
from the closely related Mycobacterium bovis, causing TB in
cattle. The BCG vaccine is one of the most widely used vaccines
ever in the world. It is effective against disseminated childhood
TB, but it fails to control pulmonary TB in adolescents and adults
(4, 5). Hence, there is an urgent medical need for designing
novel vaccines and delivery strategies, which can effectively boost
BCG-primed immune responses in adolescents and adults, and
ultimately induce protective immunity against TB (6, 7).
After infection in the lungs, Mtb adopts a variety of immune
evasion strategies, which chiefly includes suppression of an
innate immune response and subsequently delaying T cell
responses in the lungs by approximately 2 weeks (8). These
evasion strategies enable Mtb to proliferate in the lungs (8–
10), eventually explaining the poor efficacy of parenteral BCG
vaccination in humans (8, 11). Therefore, homologous or
heterologous boost immunization strategies aiming at inducing
T-cell immunity in the lungs have the potential to fill this gap
(6, 10, 12). Recent preclinical studies have reported induction
of protective T-cell immunity in the lungs upon mucosal
vaccination via the airways (13–18). Mucosal immunization
in the lungs has been shown to activate local dendritic
cells (DCs) (19) to induce antigen-specific T cells, which
effectively home back to the lung parenchyma, where they
control initial Mtb replication after infection (6, 18). However,
almost all TB vaccine candidates in the global clinical pipeline
Abbreviations: BCG, Bacillus Calmette–Guérin; CAF01, cationic adjuvant
formulation 01; CT, computed tomography; DC, dendritic cell; DDA;
dimethyldioctadecylammonium; DTPA, diethylenetriamine pentaacetic acid; Ga,
gallium; ILN, inguinal lymph node; In, indium; i. pulmon., intrapulmonary; ITLC,
instant thin layer chromatography; MBq, megabecquerels; MLN, mediastinal
lymph node; Mtb, Mycobacterium tuberculosis; NOTA, 1,4,7-triazacyclononane-
1,4,7-triacetic acid; PDI; polydispersity index; PLN, popliteal lymph node; Rf,
retention factor; SPECT, single-photon emission computed tomography; SUV,
standardized uptake value; TB, tuberculosis; TDB, trehalose-6,6’-dibehenate, TLN,
tracheobronchial lymph node; VOI, volume of interest.
are administered parenterally (20). Subunit vaccines based on
adjuvanted, recombinant TB proteins represent an attractive
approach for airway mucosal vaccination (21–23). Besides,
vaccine delivery in lungs through inhalation may circumvent
the potential safety concerns associated with administration of
gene delivery systems, live attenuated organisms, and potentially
neurotoxic adjuvant molecules through the nasal route (24,
25). However, thorough safety assessment of airway mucosal
vaccination is required.
Understanding the biodistribution and pharmacokinetics
of injectable and mucosally administered subunit vaccines is
essential (i) for shaping and orchestrating the desired immune
response and (ii) for optimal spatiotemporal targeting of the
appropriate populations and numbers of effector cells at the site
of infection in the lungs. Molecular imaging assessment of such
low-dose biological medicinal products using for example single-
photon emission computerized tomography (SPECT), allows for
the characterization and quantification of biological processes at
the cellular and subcellular level in intact living subjects with
sufficient spatial and temporal resolution (26). SPECT imaging
is based on the measurement of single photons emitted by γ-
emitting radionuclides, e.g., 99mTechnitium, 111Indium (111In),
and 67Gallium (67Ga). Furthermore, SPECT imaging is non-
invasive and quantitative, permitting uniform and repeated
measurements using a single animal subject, thus exploiting
the statistical power of longitudinal studies and reducing the
required number of animals. In addition, it allows for tracer
multiplexing, where several isotopes of different energies can
be used in the same animal. Hence, this imaging modality is
an effective substitute for conventional ex vivo biodistribution
studies, which usually require a larger number of animals
assessed at multiple time points. In addition, high structural
resolution can be achieved by combining the robustness of
morphological/anatomical [e.g., computer tomography (CT)]
and molecular imaging modalities, which is referred to as
multimodality imaging, such as SPECT/CT (26–28). SPECT/CT
imaging has been successfully applied in many areas of medical
science, but very few reports have been published on SPECT/CT
imaging-based investigations for vaccines.
The TB protein subunit vaccine H56/CAF01, which comprises
the multi-stage subunit TB fusion protein H56 (Ag85B-ESAT-
6-Rv2660c) co-formulated with the liposomal adjuvant referred
to as cationic adjuvant formulation 01 (CAF01), has been
shown to induce protective immunity before and after Mtb
exposure in preclinical models (29, 30). H56 is currently
tested in a clinical phase 2a trial with the IC31 R© (Valneva,
Lyon, France) adjuvant (31). CAF01, which is based on the
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surfactant dimethyldioctadecylammonium (DDA) bromide and
the glycolipid trehalose-6,6′-dibehenate (TDB), has been shown
to deliver antigen to and activate DCs through the Toll-like
receptor (TLR)-independent Syk-CARD9 pathway (32), and
it induces a Th1- and Th17-biased CD4+ T cell response
along with a humoral immune response (33, 34). In clinical
phase I trials, CAF01 has been found safe, well-tolerated
and immunogenic when co-administered with a protein-based
TB antigen (NCT00922363) or a cocktail of HIV-1 peptides
(NCT01141205). In preclinical studies in mice, CAF01 mixed
with H56 has been shown to be safe and immunogenic
following intranasal prime and/or boost immunizations (22).
Thus, H56/CAF01 is a safe and efficacious multi-faceted TB
vaccine.
In this study, we tested for the first time mucosal application
of H56/CAF01 using intrapulmonary (i.pulmon.) administration
in the airways. We also report the first radiolabeling and
preclinical SPECT/CT imaging of the biodistribution and
pharmacokinetics of a subunit vaccine. We provide compelling
evidence that mucosal administration of H56/CAF01 in
the airways induces high levels of antigen-specific lung
mucosal IgA and polyfunctional CD4+ T-cell responses
following intramuscular (i.m.) priming and i.pulmon. mucosal
boost immunization. In addition, strong systemic IgA and
polyfunctional CD4+ T-cell responses are induced, which are
comparable to the systemic responses induced upon homologous
i.m. prime-boost immunization. We show successful dual-
isotope radiolabeling of H56 and CAF01 with 111In and 67Ga and
observe pronounced differences in the pharmacokinetics of H56
and CAF01 following i.pulmon. immunization. Hence, this study
underlines the promising potential of H56/CAF01 as a vaccine
candidate for airway mucosal immunization, and thus provides
the basis for its further preclinical and clinical development as
an inhalable and self-administrable aerosol vaccine.
MATERIALS AND METHODS
Materials
DDA and 18:0 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-diethylenetriaminepentaacetic acid
(ammonium salt) (PE-DTPA) were obtained from Avanti
Polar Lipids (Alabaster, AL, USA), and TDB was purchased
from Niels Clauson-Kaas A/S (Farum, Denmark). S-2-(4-
Isothiocyanatobenzyl)-diethylenetriamine pentaacetic acid
(p-SCN-Bn-DTPA) and 2-S-(4-Isothiocyanatobenzyl)-1,4,7-
triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) were
procured from Macrocyclics (Plano, TX, USA). Recombinant
H56 protein was produced in E. coli as previously described
(35). It was reconstituted in 20mM glycine buffer (pH 8.8),
checked for purity and validated for residual DNA, endotoxins
and bioburden following internal good manufacturing practice
standards. All other chemicals and reagents were of analytical
grade and were acquired from commercial suppliers.
Preparation and Physicochemical
Characterization of Vaccine Formulations
Liposomes were prepared by using the thin film method and
characterized for average intensity-weighted hydrodynamic
diameter (z-average), polydispersity index (PDI), and zeta-
potential using a Malvern Zetasizer Nano-ZS (Malvern
Instruments, Worcestershire, UK) by dynamic light scattering
using photon correlation spectroscopy and Laser-Doppler
electrophoresis, respectively, as previously described (33).
Briefly, weighed amounts of DDA and TDB (5:1, w/w) were
dissolved in chloroform/methanol (9:1, v/v) in a round bottom
flask. The organic solvents were removed by rotary evaporation
under vacuum resulting in the formation of a thin lipid film. The
lipid film was washed twice with 99% (v/v) ethanol and dried
overnight under vacuum to remove trace amounts of the organic
solvents. On the following day, the lipid film was hydrated
with 10mM Tris buffer (pH 7.4), sonicated for 5min using
an ultrasound cleaner (Branson Ultrasonic Cleaner, Danburry,
CT, USA), and heated to 60◦C for 1 h in a water bath with
vortexing every 10th min. In addition, the liposome dispersions
were tip-sonicated 20min after the rehydration for 20 s with
a 150W Branson tip-sonicator to reduce the particle size. The
final concentration of CAF01 was 20/4 mg/mL of DDA/TDB,
corresponding to a molar ratio of 89:11. The H56 solution was
mixed with equal volumes of CAF01 liposome dispersions at
concentrations of 5 and 10µg/mL, respectively, and H56 was
allowed to adsorb to CAF01 by incubation for 30min at room
temperature (36).
Radiolabeling of CAF01 and H56
For radiolabeling of CAF01 liposomes, DDA and TDB were
dissolved in chloroform/methanol (9:1, v/v) with 18:0 PE-
DTPA (10%, w/w), and the liposome dispersions were prepared
in 100mM HEPES buffer (pH 7.0) as described above. All
H56/CAF01 vaccine formulations were radiolabeled as follows:
The 18:0 PE-DTPA (10% w/w) chelated CAF01 liposomes
were purified using 10 kDa centrifugal filters (Amicon R© Ultra
0.5mL, Merck Life Science, Hellerup, Denmark) to remove
excess chelator. For 111In-labeling, 111InCl3 (55.5 MBq, 5 µL
in 0.1M HCl) was added to purified DTPA-CAF01 in HEPES
buffer (175 µL, 100mM, pH 7.0), and the reaction mixture
was stirred (600 rpm) at room temperature for 1 h. Instant thin
layer chromatography (ITLC) showed high labeling efficiency,
and 111In-CAF01was therefore used without further purification.
The collected 111In-CAF01 dispersion was diluted to a final
volume of 275 µL with HEPES buffer, and non-labeled H56 (75
µL, 1 µg/µL) was allowed to adsorb for 30min to the liposomes
before administration.
The H56 protein in 20mM glycine buffer (pH 8.8) was buffer-
exchanged into 100mM sodium bicarbonate buffer (pH 8.3)
using 10 kDa ultracentrifugal filters (Amicon R© Ultra 0.5mL,
Merck Life Science) and incubated on an Eppendorf shaker
for 5 h at 10◦C with p-SCN-Bn-DTPA or p-SCN-Bn-NOTA,
respectively, at a molar ratio of 1:5. After 5 h, unreacted DTPA
or NOTA was removed by centrifugation through 30 kDa
centrifugal filters (Amicon R© Ultra 0.5mL, Millipore, Ontario,
Canada), washed and buffer-exchanged into 100mM HEPES
buffer (pH 7.0). For 111In-labeling, 111InCl3 (148 MBq/200 µg
of H56) was added to H56, and the mixture was incubated
for 1 h on an Eppendorf shaker at room temperature. For
67Ga-labeling, 67GaCl3 (19.5 MBq/70 µg of H56) was added to
H56 and incubated for 1 h on an Eppendorf shaker at room
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temperature. 111In-H56 or 67Ga-H56 was diluted to 500 or 350
µL, respectively, with HEPES buffer and mixed with non-labeled
or 111In-CAF01 liposomes 30min prior to immunization.
Radiolabeling Efficiency and Purity of
111In-H56, 67Ga-H56 and 111In-CAF01
The radiochemical purity and labeling efficiency were measured
by ITLC using a Tec-Control stationary phase (Biodex Medical
Systems, Shirley, NY, USA) and a 0.1M EDTA (pH 4) mobile
phase. The 111In-CAF01 and 111In-H56 or 67Ga-H56 complexes,
which have larger molecular weight, would remain at the
origin, while the free 111In elutes with the mobile phase at
the solvent front [Retention Factor (Rf) (111In-CAF01, 111In-
H56, or 67Ga-H56) = 0, Rf (free 111In3+ or free 67Ga3+) = 1].
The location of the radioactivity was assessed using a Cyclone
Phosphorimager and a photostimulable phosphor plate (Perkin
Elmer, Waltham, MA, USA). A NanoDrop spectrophotometer
(Thermo Fischer Scientific, Waltham, MA, USA) was used
to assess the protein concentration [A280 with E1% set to
20.5 L/(g·cm)] and determine the specific activity. 111In-H56
was analyzed further via 10% native- and SDS-PAGE using
established protocols in the lab.
In vivo SPECT/CT Imaging
The imaging studies, which were conducted at The University
of British Columbia, were performed in accordance with the
Canadian Council on Animal Care (CCAC), and the protocols
were approved by the Animal Care Committee (ACC) of the
University of British Columbia (A16-0150). Five-to 6-week old
healthy female C57BL/6 mice were purchased from Charles River
and allowed free access to food and water. In the first study,
mice were allocated into four groups of three individuals. All
groups were immunized s.c. (at the base of the tail toward
the right) or i.pulmon. with either 10 µg cold H56 adjuvanted
with 111In-CAF01 (125/25 µg DDA/TDB) or 10 µg 111In-
H56 adjuvanted with cold CAF01 (125/25 µg DDA/TDB) in a
total volume of 200 µL or 50 µL, respectively. In the prime-
boost immunization study, mice were distributed into two
groups of three. Two groups were primed s.c. with 200 µL
of either 5 µg cold, unadjuvanted H56 or 5 µg cold H56
adjuvanted with cold CAF01 (250/50 µg DDA/TDB). Two
weeks later, booster immunization was performed by i.pulmon.
administration of either 10 µg unadjuvanted 67Ga-H56 or 67Ga-
H56 adjuvanted with 111In-CAF01 (125/25 µg DDA/TDB) in
a total volume of 50 µL. The i.pulmon. administration was
performed using aMicroSprayer R©/Syringe Assembly (MSA-250-
M, Penn-Century, Inc., Wyndmoor, PA, USA) according to a
previously reportedmethod (37). In brief, mice were anesthetized
by intraperitoneal (i.p.) injection of Ketamine (Ketamin, MSD
Animal Health, Havneholmen, Denmark)/Xylazine (Rompun
Vet, Bayer, Copenhagen, Denmark) 100/5 mg/kg, respectively,
and placed on a rodent tilting work stand at a 45◦ angle by
the upper incisors (Hallowell EMC, Pittsfield, MA, USA). For
the prime-boost immunization study, anesthesia was induced
with 5% isoflurane, the mice were placed on a rodent tilting
intubation stand with an integrated anesthesia facemask (Kent
Scientific, Torrington, CT, USA), and anesthesia was maintained
with 3% isoflurane. A cold light source with a flexible fiber-optics
arm (SCHOTT AG, Mainz, Germany) was used for optimal
illumination of the trachea, which appeared as a white light
spot. A cotton swab was used to open the lower jaw of the
mouse, and the tongue was displaced to the left with a blunted
forceps. A laryngoscope (WelchAllen, NY, USA) fitted with a
41mm intubation specula (Halowell EMC) was used with the
other hand for maximal oropharyngeal exposure. After a clear
view of the trachea, the laryngoscope with the specula was
taken out, and 50 µL of the formulation was administered
intratracheally with the MicroSprayer R©/Syringe Assembly right
above the carina (first bifurcation) to ensure uniform delivery
into both lungs. The tip of the syringe was immediately
withdrawn, and the mouse was taken off the intubation stand.
During SPECT/CT imaging, the mice were anesthetized using
isoflurane (1–3% for maintenance, up to 5% for induction)
and oxygen from a precision vaporizer, and they received
s.c. injection of Lactated Ringer’s solution (0.5mL, B. Braun,
Mississauga, Canada) for hydration prior to the SPECT/CT
imaging scan. The SPECT/CT imaging was performed using a
VECTor/CT preclinical small animal scanner (MILabs, Utrecht,
The Netherlands). The respiratory rate and body temperature
of the mice were monitored continuously during the scans, and
the isoflurane dose and animal anesthesia bed temperature were
adjusted accordingly. All animals recovered after each scan. Mice
were euthanized 144 h post-administration using CO2, the blood
was collected by cardiac puncture, and the tissues were isolated
to quantify the biodistribution.
SPECT/CT Parameters and Image
Reconstruction
Whole-body SPECT 111In and 67Ga data were acquired using an
integrated VECTor/CT preclinical scanner (MILabs) equipped
with an XUHS-2mm mouse multi-pinhole collimator. Dynamic
whole-body scans were acquired in list-mode format over
40min (10 min/frame) post-s.c. or -i.pulmon. administration
to study the biodistribution of the protein and the liposomes
every 10min. Subsequently, static 40min scans were performed
for the 6 and 24 h scans, while longer imaging times of
60 and 90min were performed at subsequent imaging time-
points (96 and 144 h) after vaccine administration to increase
the statistical signal and the quality of the 111In and 67Ga
images. Following each SPECT acquisition, a whole-body CT
scan was acquired to obtain anatomical information, and both
images were registered. For the first imaging study, the 111In
photopeak window was centered at 171 keV with a 20%
energy window width. For assessment of the biodistribution
in the prime-boost immunization study, the 111In photopeak
window was centered at 20 keV with a 60% energy window
width, while the 67Ga photopeak was centered at 96 keV
with a 20% energy window width. For quantitative analysis,
SPECT image reconstructions were carried out using the pixel-
ordered subset expectation maximization (POSEM) algorithm
(38), which includes resolution recovery and compensation
for distance-dependent pinhole sensitivity. Further details are
provided in the Supplementary Section.
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Biodistribution
After the last scan at day 6 (144 h), blood samples were collected
by cardiac puncture, and a complete biodistribution assessment
was conducted by collecting heart, liver, kidneys, lungs, lymph
nodes (LNs), small intestine, bladder, muscle, site of injection,
spleen, stomach, bone, trachea, and pancreas. The organs were
cleaned from blood and weighed, and the radioactivity was
measured using a gamma counter (Packard Cobra II autogamma
counter, Perkin Elmer, Waltham, MA, USA). The calibration
factor for 111In was 163631 cpm and 67Ga was 78395 cpm
(instrument-specific). The total weight of the organs was used to
calculate the administered dose per organ (%AD/organ).
Immunizations
Six-to 8-week old female CB6F1 (BALB/c x C57BL/6, Scanbur,
Karlslunde, Denmark) hybrid mice were acquired and
acclimatized for 1 week before experimental manipulation.
All experimental work related to vaccine immunogenicity
was performed at University of Copenhagen and approved by
the Danish National Experiment Inspectorate under permit
2016-15-0201-01026. The studies were performed in accordance
with the European Community directive 86/609 for the care and
use of laboratory animals. Mice were assigned to five groups
of six individuals, and they were immunized three times using
a dose volume of 50 µL of Tris buffer (pH 7.4) at 2-week
intervals, which is in line with our previous studies showing
that three immunizations are required when applying the
s.c. route of administration for optimal immune stimulation
(29, 39). The immune responses were evaluated 2 weeks after
the final immunization. All vaccine priming was performed by
i.m. administration in the right thigh muscles, while the two
booster immunizations were given i.pulmon. The first group of
mice was primed with saline (n = 3) and 5 µg unadjuvanted
H56 (n =3), respectively, and boosted i.pulmon. with 10 µg
unadjuvanted H56. The second group (250/50 3∗i.m., n = 6)
was primed and boosted i.m. with 5 µg H56 adjuvanted with
CAF01 at a dose of 250/50 µg DDA/TDB. Groups 3–5 (n =
6 each) were all primed i.m. with 5 µg H56 adjuvanted with
CAF01 at a dose of 250/50 µg DDA/TDB. These three groups
were boosted i.pulmon. with 10 µg H56 adjuvanted with CAF01
at a dose of 125/25 (125/25 i.m./2∗i.pulmon.) and 250/50 (250/50
i.m./2∗i.pulmon.) for groups 3 and 4, respectively, and 500/100
µg DDA/TDB (500/100 i.m./2∗i.pulmon.) for group 5. CAF01
alone does not induce immunological responses (40, 41). Hence,
it was not included as a control in this study. In addition, we
have previously shown that there is no difference between s.c.
(29) and i.m. (42) immunization with the H56/CAF01 vaccine in
mice with respect to immunogenicity and protection against TB
infection. Hence, we chose the i.m. route of administration for
evaluation of vaccine immunogenicity.
In vivo Staining
Anti-CD45.2 FITC (clone 104; BD Biosciences, Lyngby,
Denmark) was diluted to 10µg/mL in sterile PBS, and 250 µL
of the diluted antibody was injected (i.v.) via the tail vein 3min
prior to euthanasia of the CB6F1 mice.
Sample Collection and Cell Preparation
Blood samples were taken by cardiac puncture. Serum was
isolated by allowing the blood to clot at room temperature, and
the clot was removed by centrifugation at 2,000 × g for 10min.
Subsequently, serum was collected and stored at −20◦C. The
lungs were aseptically removed from the euthanized mice and
transferred to gentleMACS C tubes (Miltenyi Biotec Norden
AB, Lund, Sweden) containing 2mL of RPMI 1640 (Sigma-
Aldrich, Brøndby, Denmark), 5% (v/v) FCS (Gibco Thermo
Fisher, Hvidovre, Denmark) and 0.8 mg/mL collagenase type
IV (Sigma-Aldrich, St. Louis, MO, USA). They were dissociated
into 1-2mm sized pieces using the gentleMACS dissociator
(Miltenyi Biotec Norden AB). After 1 h incubation at 37◦C,
the lung pieces were dissociated again using the gentleMACS
dissociator and centrifuged at 700 × g for 5min. The lung
supernatants were collected and stored at −20◦C until antibody
detection. The lung cell pellets were homogenized using a
cell strainer (Falcon, Durham, NC, USA) and washed twice
using RPMI-1640 (Sigma-Aldrich). The spleen, the lung-draining
tracheobronchial and mediastinal lymph nodes (TLNs and
MLNs) and lymph nodes draining the site of i.m. injection,
i.e., inguinal (ILNs) and popliteal lymph nodes (PLNs), were
aseptically collected. Single-cell suspensions were obtained from
the spleens and draining LNs by homogenizing the organs
through a nylon mesh cell-strainer (Falcon) followed by two
washings with RPMI 1640. The cells were grown in microtiter
plates (Nunc, Roskilde, Denmark) containing 2 × 105 cells per
well for cytokine assays, or 1 × 106 cells per well for flow
cytometry in 100 µL RPMI-1640 (Sigma-Aldrich) supplemented
with 5 × 10−5 M 2-mercaptoethanol (Gibco Thermo Fisher),
1% (v/v) sodium pyruvate (Sigma-Aldrich), 1% (v/v) penicillin-
streptomycin (Gibco Thermo Fisher), 1%HEPES (Gibco Thermo
Fisher), and 10% (v/v) FCS (Gibco Thermo Fisher).
Antibody Detection
MaxisorpTM plates (Nunc) were coated with 0.5µg/mL of
H56 solution. Serum and lung supernatants were 5-fold or
10-fold serially diluted 8-12 times from a 1:1 dilution with
bicarbonate buffer. IgA, IgG1, IgG2a, IgG2b, IgG2c, and IgM
were detected with HRP-conjugated secondary antibodies
(Supplementary Table S1). 3,3′,5,5′-tetramethylbenzidine
(TMB) Plus2 (Kem-En-Tec, Taastrup, Denmark) was used as
substrate. Non-linear regression analysis was performed on
serum O.D. values to calculate the ELISA mid-point titers, i.e.,
EC50 as previously described (43).
Cytokine Assays
For the IFN-γ and IL-17A assays, lung and spleen cells
were stimulated with 2µg/mL H56 antigen. Wells containing
medium alone or 5µg/mL concanavalin A (Sigma-Aldrich) were
included as negative and positive controls, respectively. The
supernatants were harvested after 72 h incubation at 37◦C/5%
CO2, and the IFN-γ and IL-17A production were quantified
by using a standard ELISA protocol. Briefly, purified rat
anti-mouse IFN-γ and IL-17A (Biolegend, San Diego, CA,
USA) were used as capture antibodies, and biotin-conjugated
rat anti-mouse IFN-γ and IL-17A (Biolegend) were used as
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detection antibodies, followed by HRP-conjugated streptavidin
(BD Biosciences, Kongens Lyngby, Denmark) and TMB Plus2
ready-to-use substrate (Kem-En-Tec). The enzymatic reaction
was stopped at optimal color development with 0.2M H2SO4,
and the absorbance was read at a wavelength of 450 nm.
Flow Cytometry
The isolated lung, spleen and lymph node cells were stimulated
in vitro in media containing 1µg/mL anti-CD28 (37.51; BD
Biosciences) and 1µg/mL anti-CD49d (9C10; BD Biosciences)
without antigen, or in the presence of 2µg/mL H56 for
1 h, followed by incubation for 5 h at 37◦C in the presence
of 10µg/mL brefeldin A (Sigma-Aldrich) and 0.7 µL/mL
monensin/Golgi-stop (BD Biosciences). Following overnight
storage at 4◦C, the cells were washed with FACS buffer [PBS
containing 0.1% (w/v) sodium azide and 1% (v/v) FCS] and
stained for 30min at 4◦C for surface markers using anti-CD4-
APC-eF780 (RM4-5; eBioscience, San Diego, CA, USA) and anti-
CD44-APC (IM7; Biolegend) mAbs. For intracellular staining,
cells were washed with FACS buffer, fixed and permeabilized
using the Cytofix/Cytoperm kit (BD Biosciences) and stained
for 30min at 4◦C for intracellular cytokines using anti-
IFN-γ-PE-Cy7 (XMG1.2; eBioscience), anti-TNF-α-PE (MP6-
XT22; eBioscience), and anti-IL-17A-PerCP-Cy5.5 (eBio17B7;
eBioscience). Cells were twice washed, resuspended in FACS
buffer and analyzed using an LSRFortessa flow cytometer
(BD Biosciences). Gates for the surface markers are based on
fluorescence-minus-one controls. All flow cytometric analyses
were performed using the FlowJo software v10 (Tree Star,
Ashland, OR, USA).
Statistical Analysis
GraphPad Prism software (Graphpad Software Inc, La Jolla,
CA, USA) was used to perform all statistical analyses.
SPECT/CT imaging-based SUVs and ex vivo biodistributions
were compared between the groups by two-way ANOVA and
multiple comparisons were performed by Sidak’s post-test.
Immune responses were compared between the groups by
ANOVA (IFN-γ and IL-17 responses, and antibody responses
measured by ELISA) or two-way ANOVA (polyfunctional T
cells) at a 0.05 significance level, and pair-wise comparison was
performed using Tukey’s post-test. A value of p < 0.05 was
considered significant.
RESULTS
Radiolabeling of CAF01 Liposomes and
H56 Protein Does Not Influence Their
Physicochemical Characteristics
CAF01 was prepared by using the thin film method combined
with ultrasonication as previously described (44). The resulting
unilamellar liposomes had an average hydrodynamic diameter of
approximately 153± 17 nm, a PDI of 0.324± 0.048 (Figure 1A),
and a zeta-potential of 63.6 ± 11.7 (n = 5, results not shown),
which are in accordance with previously reported values for
CAF01 prepared using the same method (44–46). The chelation
with 18:0 PE-DTPA significantly decreased the size of the CAF01
liposomes (average size = 123 ± 11 nm, PDI = 0.270 ± 0.021,
Figure 1A, zeta-potential= 69.9± 8.2, n= 8, results not shown).
However, the subsequent radiolabeling with 111In (average size=
149.8 ± 36 nm, PDI = 0.292 ± 0.092, Figure 1A, zeta-potential
= 55.8 ± 8.52, n = 3, results not shown) had no effect on
the physicochemical properties of CAF01 liposome dispersions
as their hydrodynamic diameter, PDI and zeta-potential are
maintained after radiolabeling (Figure 1A). The radiochemical
purity and labeling efficiency of 111In-CAF01 (Figure 1B), 111In-
H56 (Figure 1C) and 67Ga-H56 (Figure 1D) were measured
using ITLC. 111In-labeling of both CAF01 and H56 using
the 18:0 PE-DTPA and p-SCN-Bn-DTPA chelator, respectively,
was consistently accomplished with labeling efficiencies of
approximately 95% for 111In-CAF01 (Figure 1B) and 80% for
67Ga-H56 (Figure 1C). The average number of bound DTPA
molecules was 5 per molecule lipid molecule in CAF01 and
1 per molecule of H56, and the average number of bound
NOTA molecules was 1 per molecule of H56. 67Ga-labeling of
H56 using the p-SCN-Bn-NOTA chelator resulted in labeling
efficiencies of ∼93% (Figure 1D). The protein concentrations of
the radiolabeled 111In-H56 and 67Ga-H56 were 1 and 0.9 mg/mL,
respectively. Both 111In- (Figure 1E) and 67Ga-labeled H56
protein (Figures 1F,G) displayed their original molecular weight
of 48 kDa (36) determined using SDS-PAGE, suggesting that the
radiolabeling procedure did not cause any major modification of
the overall size of H56. These data suggest that radiolabeling does
not affect the physicochemical properties of CAF01 and H56.
The H56/CAF01 Vaccine Remains in the
Lungs Following i.pulmon. Immunization,
Whereas Un-Adjuvanted H56 Rapidly
Drains to the Local Lymph Nodes
First, we evaluated the biodistribution and kinetics of the
H56/CAF01 vaccine upon pulmonary administration. Mice were
dosed i.pulmon. with cold H56 + 111In-CAF01 or 111In-H56 +
cold CAF01, respectively, and the vaccine biodistribution and
pharmacokinetics were visualized and quantified by SPECT/CT
imaging at designated time points post-injection (Figure 2A).
On day 6, the mice were euthanized, and the remaining activity
was measured in different organs using a gamma counter. The
SPECT/CT images permitted precise anatomical localization
of 111In-CAF01 and 111In-H56 in the animals (Figures 2B,C).
The images clearly reflect pronounced differences in the
pharmacokinetics of H56 and CAF01 following i.pulmon.
administration, and H56 was cleared much faster from the
lungs than CAF01. Initially, the vaccine (H56 and CAF01) was
apparently distributed evenly in the lungs, and it remained in the
lungs during the first 30min post-injection. Administration via
the i.pulmon. route often results in deposition of a certain dose
fraction of the radiopharmaceutical in the back of the mouth,
which is subsequently swallowed (47). Hence, this dose fraction
will redistribute to the stomach and the upper gastrointestinal
tract, as observed in the 6 h scan. By 6 h, H56 as well as
CAF01 were slowly cleared from the stomach and the intestines,
and continued to transit in the gut up to 24 h after dosing.
The H56 protein could only be detected in the animals up to
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FIGURE 1 | Physicochemical properties of radiolabeled CAF01 liposomes and H56 protein. (A) Chelation of DTPA and radiolabeling of CAF01 with 111 In do not
significantly influence the average intensity-weighted hydrodynamic diameter (z-average, circles, left axis) and polydispersity index (PDI) (squares, right axis),
respectively. Statistical analysis: two-way ANOVA and Tukey’s post-test. Bars represent mean values ± s.d., n = 5 (CAF01), n = 8 (CAF01-DTPA), and n = 3
(111 In-DTPA-CAF01). *p < 0.05 and **p < 0.001. (B) Instant thin layer chromatography (ITLC) analysis of 111 In-DTPA-CAF01. Free 111 In3+ migrates with the solvent
front (Rf = 1.0), whereas
111 In-DTPA-CAF01 stays at the origin (Rf = 0). Left is
111 In-DTPA-CAF01 for s.c. injection and right is 111 In-DTPA-CAF01 for i.pulmon.
administration. (C) ITLC analysis of 111 In-DTPA-H56, where free 111 In3+ migrates with the solvent front (Rf = 1.0, left) and
111 In-DTPA-H56 stays at the origin (Rf =
0, right). (D) ITLC analysis of 67Ga-NOTA-H56, where 67Ga-NOTA-H56 stays at the origin (Rf = 0). (E) SDS-PAGE analysis of
111 In-labeled H56 protein. Lane A
represents a protein ladder, lane B is unmodified H56 protein, lane C is 111 In-DTPA-H56 protein, and lane D is 111 In-DTPA-H56 protein showing the phosphorimager
radioactivity signal. (F) SDS-PAGE analysis of 67Ga-labeled H56 protein. Lane 1 represents the protein ladder, lane 2 is NOTA-H56, and lane 3 is 67Ga-NOTA-H56
protein. (G) Phosphorimager radioactivity signal from 67Ga-NOTA-H56 protein.
24 h post administration (Figure 2C), as compared to CAF01,
which remained longer in the lungs and was detectable until
termination of the experiment (day 6), although with a time-
dependent decline in signal intensity (Figure 2B). Quantification
of the in vivo biodistribution (SUV values) supported these
observations (Figure 2D). The activity observed in the lungs
for CAF01 was relatively higher than the activity measured
for H56 during the entire experiment (Figure 2D, upper left).
Both H56 and CAF01 showed very low activity in the trachea,
kidneys and bladder at the designated time-points, except at
the initial 30min, where a high activity was detected. Notably,
a higher activity was also measured in the stomach 6 and
24 h post injection for H56 than for CAF01, although there
was no difference in the intestinal activity at these time points
(Figure 2D, lower right). Whole body activity was measured
on day 6 after euthanizing the animals and compared to the
total administered dose, and the percentage of the administered
dose per organ/tissue was calculated (Figure 2E). The SPECT/CT
image analysis corroborate with the ex vivo biodistribution
data, which showed that the major part of the radioactive
dose was recovered in the lungs (Figure 2E). However, there
was a statistically significant difference between the remaining
activity of H56 and CAF01 in the left lung. For CAF01, a
relatively low dose fraction of the radioactivity was found in the
liver, kidneys and muscle. In contrast, H56 was detectable in
relatively higher amounts in the liver and the kidneys, confirming
a faster metabolism and elimination of H56 than CAF01. A
comparatively higher activity of H56 than CAF01 was also
observed in other organs, including the lung-draining LNs, which
confirms the pronounced differences in the biodistribution and
pharmacokinetics of H56 and CAF01.
The Vaccine Forms a Depot Following
Parenteral (s.c.) Administration
For control and comparative purposes, we examined the
biodistribution of the H56/CAF01 vaccine following parenteral
administration. Mice were injected s.c. with either 111In-CAF01
or 111In-H56 with cold H56 or cold CAF01, respectively, and
the vaccine biodistribution was visualized and quantified by
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FIGURE 2 | The H56/CAF01 vaccine remains in the lungs following i.pulmon. administration, whereas H56 drains to the local lymph nodes. (A) Experimental scheme:
Mice were exposed i.pulmon. to 10 µg cold H56 adjuvanted with 111 In-CAF01 (125/25 µg DDA/TDB) and 10 µg 111 In-H56 adjuvanted with cold CAF01 (125/25 µg
DDA/TDB), respectively. Animals were imaged by dynamic whole-body SPECT/CT scan for the initial 40min (10 min/frame) and after that static 40min scans at 6 and
24 h, 60min scan at 96 h and 90min scan at 144 h were conducted. Animals were euthanized on day 6 after immunization for ex vivo quantification of the
biodistribution using a gamma counter. Representative SPECT/CT images of a mouse dosed i.pulmon. with cold H56 + 111 In-CAF01 (B) or 111 In-H56 + cold CAF01
(C) and imaged over 144 h post-immunization. (D) Organ SUVs in g/mL of the cold H56 + 111 In-CAF01 or 111 In-H56 + cold CAF01 over 144 h post-immunization;
calculated from dynamic and static SPECT/CT images. Statistical analysis: two-way ANOVA and Sidak’s post-test. Data represent mean values ± s.d., n = 3. *p <
0.05, ***p < 0.001, and ****p < 0.0001. (E) Ex vivo organ biodistribution [% administered dose (AD)/organ] of the cold H56 + 111 In-CAF01 or 111 In-H56 + cold
CAF01 on day 6 (144 h) post-immunization. Statistical analysis: two-way ANOVA and Sidak’s post-test. Bars represent mean values ± s.d., n = 3. **p < 0.01.
SPECT/CT imaging at the designated time-points up to 144 h
post-immunization (Figure 3A). Mice were euthanized 144 h
post-injection for ex vivo quantification of the biodistribution.
The SPECT/CT images clearly showed 111In-CAF01 and 111In-
H56, respectively, in the animals at the site of injection
(Figures 3B,C). CAF01 and H56 displayed a highly comparable
biodistribution after s.c. administration, and the major part of
the dose remained at the injection site for the entire duration
of the experiment, suggesting the formation of a vaccine depot
at the site of injection, as previously published (48). However,
the activity of 111In declined during the experiment to a
minimal level 144 h post-injection. A high activity was observed
at the injection site for both CAF01 and H56 (Figure 3D),
which declined until 144 h (Figure 3D, upper left). However, a
significantly lower activity was detected for H56, as compared
to CAF01, up to 30min post-injection. Due to their relatively
large size and cationic charge, CAF01 liposomes stayed at
the injection site as previously published (48), and almost no
activity of 111In-CAF01 was observed in the kidneys and the
bladder post-injection. In contrast, H56 was cleared faster from
the injection site and was subsequently excreted through the
kidneys, which was evident from the 6, 24, and 96 h post-
injection images (Figure 3D, upper right and lower left) and
a correspondingly higher activity for H56 in the bladder than
CAF01 (Figure 2D, upper middle). The initial sharp increase
in 111In activity within 30min post-injection was due to free
111In (Figure 2D, upper middle) in the radiopharmaceutical.
Almost no activity was observed in the stomach and the intestines
following s.c. immunization (Figure 3D, lowermiddle and right).
As expected, most of the radioactivity was detected at the site of
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injection (Figure 3E). For CAF01, a relatively low dose fraction of
radioactivity was found in the liver, kidneys, and muscle, which
was collected from the right thigh close to the site of injection.
In contrast, radioactivity for H56 was observed in several other
organs besides the liver, kidney and muscle. Comparing the
two, the radioactivity in the kidneys was statistically significantly
higher for H56 than for CAF01, which correlates well with the
SPECT/CT image analyses. Hence, the SPECT/CT and the ex
vivo biodistribution data collectively confirm that the major dose
fraction of CAF01 stays at the site of injection following s.c.
injection, while a small dose fraction of H56 is cleared slowly
from the injection site into the blood stream and is subsequently
excreted through the kidneys.
Combined Parenteral (i.m.) Prime and
Airway (i.pulmon.) Boost Immunizations
Increase H56-Specific IgA Titers in the
Airways
With the objective to establish an immunization protocol
that generates strong local IgA responses in the airways,
we compared vaccine-induced lung IgA responses using
two different vaccination strategies; i.m. prime/i.m. boost
and i.m. prime/i.pulmon. boost immunization. Mice were
immunized twice with CAF01-adjuvanted H56 via the i.m./i.m.
or i.m./i.pulmon. administration routes, respectively, using
different doses of CAF01 to determine the optimal adjuvant
dose. Subsequently, we measured H56-specific IgA, IgG1, IgG2a,
IgG2b, IgG2c, and IgM antibodies in the lung homogenate
supernatants, as well as the IFN-γ and IL-17 production by
H56-restimulated lung cells 2 weeks after the last booster
immunization. For the antibody responses, the mid-point
titers were calculated from O.D. values measured by ELISA.
Significantly higher levels of H56-specific IgA responses in the
lungs (Figure 4A) and the serum (Figure 4B) were measured
for the three groups immunized i.m./i.pulmon, as compared
to the levels measured for mice immunized three times i.m.
Similarly, the lung (Figure 4C) and serum IgG1 responses
(Figure 4D) were significantly higher following i.m./i.pulmon.
immunization using the lowest (125/50 µg DDA/TDB) and
the highest CAF01 dose (500/100 µg DDA/TDB) than 250/50
3∗i.m. immunization. For the other IgG isotype responses in
the lungs (Figures 4E,G,I), no difference was observed between
i.m./i.m. vs. i.m./i.pulmon. immunization schedules, except for
the IgG2b responses (Figure 4G), which were higher for the
animals immunized using the i.m./i.pulmon. than for the animals
immunized using i.m./i.m. schedule. However, the lung IgG2a
responses were lower for 500/100 i.m./2∗i.pulmon. as compared
to 250/50 3∗i.m. immunization (Figure 4E). In general, the serum
H56-specific IgG isotype production was higher for all three
groups immunized i.m./ i.pulmon., as compared to the titers
for the group immunized three times i.m. (Figures 4D,F,H,J).
However, the H56-specific IgG2b responses were lower in the
125/25 i.m./2∗sngsjehdlejhdx, ki.pulmon. group (Figure 4H). As
expected, IgM was only detected at low levels in serum and lung
homogenates (Supplementary Figure S1).
Correlating with these findings, i.m./i.pulmon. immunization
induced high IFN-γ levels in the lungs (Figure 4K), and the
IFN-γ levels were significantly higher for mice vaccinated
once i.m. followed by 500/100 i.m./2∗i.pulmon. as compared
to three i.m. immunizations (250/50). On the other hand,
the IL-17 responses in the lungs were significantly lower for
both 250/50 i.m./2∗i.pulmon. and 500/100 i.m./2∗i.pulmon.
than 250/50 3∗i.m. immunization (Figure 4L). However, the
125/25 i.m./2∗i.pulmon. immunization-induced IL-17 responses
were not significantly different from the responses for mice
immunized three times i.m.. In contrast to the local lung
responses, the systemic IFN-γ and IL-17 responses measured
in serum were significantly higher for the mice immunized
three times i.m. (250/50) as compared to all three i.m./i.pulmon.
immunizations (Figures 4M,N). Overall, i.m./i.pulmon.
immunization induced higher local and systemic antibody and
dose-dependent equivalent cytokine responses than 250/50
3∗i.m. immunization.
Parenteral (i.m.) Prime and Airway
(i.pulmon.) Boost Immunization Cause
Localization of H56-Specific Th1 and Th17
Cells in the Lung Parenchyma
Subsequently, we measured in further detail the T-cell
recruitment, which takes place in i.m.-primed animals during
airway mucosal boost (i.pulmon.) immunization, as compared to
animals receiving an i.m. boost (Figure 5A). First, we examined,
if H56-specific T cells were localized in the lung parenchyma
or in the lung vasculature by subjecting immunized mice to in
vivo intravascular staining. A FITC-labeled anti-CD45 mAb was
injected i.v. 3min before euthanizing the animals, which resulted
in FITC staining of all intravascular, but not parenchymal
lymphocytes, as previously described (49). Subsequently, we
identified the i.v. CD45− and CD45+ populations of H56-
specific CD4+CD44+ T cells producing IFN-γ, TNF-α and
IL-17, respectively, 2 weeks after the last immunization by
intracellular cytokine staining. The i.m./i.pulmon. immunization
strategy caused markedly elevated infiltration of CD4+CD44+
T cells in the lungs, as compared to i.m./i.m. immunization
(Figures 5B,C). Most of these cells were localized in the lung
parenchyma, and the percentage of IFN-γ, TNF-α, or IL-17
cytokine-producing i.v.CD45− cells was significantly higher
for 125/25 i.m./2∗i.pulmon. and 250/50 i.m./2∗i.pulmon. than
250/50 3∗i.m. group (Figure 5B). A similar trend was observed
when we examined the frequencies of each of the single
cytokine-producing i.v. CD45−CD4+CD44+ T cells among the
different immunization groups (Supplementary Figure S2A).
The functionality of the antigen-specific CD4+CD44+ T cells
was determined with respect to their expression of IFN-γ,
TNF-α and IL-17, respectively, or their combinations, for
both immunization strategies by combinatorial Boolean gating
analysis (Figure 5C). The polyfunctionality of the CD4+CD44+
T cells is represented pictorially by pie charts after deduction
of control group responses from all immunization groups. The
i.m./i.pulmon. immunization induced primarily polyfunctional
T-cell populations consisting of double (IFN-γ+TNF-α+ and
TNF-α+IL-17+) and triple (IFN-γ+TNF-α+IL-17+) positive
cytokine-producing memory CD4+CD44+ T cells and a lower
Frontiers in Immunology | www.frontiersin.org 9 November 2018 | Volume 9 | Article 2825
Thakur et al. SPECT/CT and Mucosal Immunization of H56/CAF01 Vaccine
FIGURE 3 | The H56/CAF01 vaccine forms a depot at the site of injection following s.c. administration. (A) Experimental scheme: S.C. immunization was carried out
with 10 µg cold H56 adjuvanted with 111 In-CAF01 (125/25 µg DDA/TDB) or 10 µg 111 In-H56 adjuvanted with cold CAF01 (125/25 µg DDA/TDB). Dynamic
whole-body SPECT/CT scans were carried out for 40min (10 min/frame) and thereafter static 40min scans at 6 and 24 h, 60min scan at 96 h and 90min scan at
144 h were performed. Animals were euthanized on day 6 after immunization for ex vivo quantification of the biodistribution using a gamma counter. Representative
SPECT/CT images of a mouse injected s.c. with cold H56 + 111 In-CAF01 (B) and 111 In-H56 + cold CAF01 (C), imaged over 144 h post-administration. (D) Organ
SUVs in g/mL of the cold H56 + 111 In-CAF01 or 111 In-H56 + cold CAF01 over 144 h post-immunization; calculated from dynamic and static SPECT/CT images.
Statistical analysis: two-way ANOVA and Sidak’s post-test. Data represent mean values ± s.d., n = 3. *p < 0.05, **p < 0.01, and ****p < 0.0001. (E) Ex vivo organ
biodistribution (% administered dose (AD)/organ] of the cold H56 + 111 In-CAF01 or 111 In-H56 + cold CAF01 on day 6 (144 h) post-immunization. Statistical analysis:
two-way ANOVA and Sidak’s post-test. Bars represent mean values ± s.d., n = 3. **p < 0.01.
frequency of single (IFN-γ+, TNF-α+, or IL-17+) cytokine-
positive effector CD4+CD44+ T cells (Figure 5C, pies). This
shows that there is a CAF01 dose-dependent increase in the
frequency of terminally differentiated effector CD4+CD44+ T
cells producing IFN-γ+ alone (Figure 5C, blue pies), whereas
immunization with a lower dose of CAF01 led to more IL-17
producing memory-line T cells also expressing TNF-α with
or without expression of IFN-γ (Figure 5C, red and light blue
pies). However, there was a dose-dependent increase in the IFN-
γ
+TNF-α+ producing CD4+CD44+ T cells (Figure 5C, orange
pies). In agreement with the stronger antibody and cytokine
responses measured above, there was a higher frequency of
H56-specific, cytokine-producing memory CD4+CD44+ T
cells in the lungs following i.m./i.pulmon. immunization, as
compared to the 250/50 3∗i.m. immunization, which induced
very low levels of these cells (Figure 5C, bars). Among the
three groups immunized using i.m./i.pulmon. vaccination,
immunization at the lowest CAF01 dose (125/25 µg DDA/TDB)
induced consistently higher frequencies of cytokine-producing
single, double, and triple cytokine-producing CD4+CD44+ T
cells, except IFN-γ+TNF-α+ subgroup, where immunization
with 250/50 µg DDA/TDB induced the highest frequency of
IFN-γ+TNF-α+ producing CD4+CD44+ T cells.
T cells were also measured in the lymph nodes draining
the lungs (TLNs + MLNs) in immunized mice (Figures 5D,E).
I.m./2∗i.pulmon. immunization with 125/25 and 500/100 µg
DDA/TDB led to a markedly higher frequency of IFN-γ,
TNF-α, and IL-17 cytokine-producing CD4+CD44+ T cells as
compared with 250/50 3∗i.m. immunization (Figure 5D). At
the individual cytokine level, i.m./i.pulmon. immunization with
the highest CAF01 dose (500/100 µg DDA/TDB) induced the
highest CD4+CD44+ T-cell levels (Supplementary Figure S2B).
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FIGURE 4 | Strong antibody and cytokine responses in the lungs and serum after parenteral (i.m.) prime and airway (intrapulmonary, i.pulmon.) mucosal boost
immunization with H56/CAF01. Mice were primed i.m. and boosted twice i.m. (5/250/50 µg H56/DDA/TDB) or primed i.m. (5/250/50 µg H56/DDA/TDB) and boosted
twice i.pulmon. (10/125/25 or 10/250/50 or 10/500/100 µg H56/DDA/TDB) at 2 weeks interval with H56 adjuvanted with different doses of CAF01 (DDA/TDB). IgA
(A,B), IgG1 (C,D), IgG2a (E,F), IgG2b (G,H), and IgG2c (I,J) mid-point titers (log EC50 values) were determined in homogenized lung supernatants and serum at 2
weeks after the last boost immunization. Lung cells (K,L) and splenocytes (M,N) were isolated 2 weeks after the last boost immunization and in vitro stimulated with
H56 for 72 h and IFN-γ and IL-17 levels were determined by ELISA. Statistical analysis: one-way ANOVA and Tukey’s post-test. Bars represent mean values ± s.e.m.,
n = 6. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
The i.m./i.pulmon. immunization induced a polyfunctional
T-cell population consisting of single (IFN-γ+ and TNF-
α
+, respectively) cytokine-positive effector CD4+CD44+ T
cells, double (IFN-γ+TNF-α+ and TNF-α+IL-17+) positive,
cytokine-producing memory CD4+CD44+ T cells and triple
(IFN-γ+TNF-α+IL-17+) cytokine-positive CD4+CD44+ T cells
(Figure 5E, pies). For the groups immunized i.m./i.pulmon.,
there was a dose-dependent decrease in the relative frequency
of double-positive (TNF-α+IL-17+) and triple-positive
CD4+CD44+ T cells (Figure 5E, red pies). In contrast to
observations in the lungs, the IFN-γ+TNF-α+ producing
CD4+CD44+ T cells in the draining lymph nodes did not show a
dose-dependent increase after i.m./i.pulmon. immunization, and
the highest fraction of cells was observed after i.m./i.pulmon.
immunization with 250/50 µg DDA/TDB (Figure 5E, orange
pies). As in the lungs, noticeably higher frequencies of memory
CD4+CD44+ T cells were observed in the TLNs and MLNs
following i.m./i.pulmon. immunization, as compared to the
frequencies after i.m. immunization (Figure 5E, bars), and
immunization with 125/25 µg DDA/TDB induced higher
frequencies of all subsets of cytokine-producing CD4+CD44+ T
cells, except for the IFN-γ+TNF-α+ producing subset.
H56-Specific Th1 and Th17 Cells Are
Induced in the Spleen Upon Parenteral
(i.m.) Prime and Airway (i.pulmon.) Boost
Immunization
Systemic induction of H56-specific Th1 and Th17 cells in
the spleen was also investigated (Figure 6A). In general, the
i.m./i.pulmon. vaccination strategy resulted in induction of
lower relative frequencies of CD4+CD44+ T cells in the
spleen, as compared to i.m./i.m. immunization (Figures 6B,C).
Interestingly, immunization with 125/25 µg DDA/TDB
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FIGURE 5 | Robust T-cell responses in the lungs and the lung-draining tracheobronchial and mediastinal lymph nodes (TLN + MLN) by parenteral (i.m.) priming and
airway (intrapulmonary, i.pulmon.) mucosal H56/CAF01 immunization. Mice were primed i.m. and boosted twice i.m. (5/250/50 µg H56/DDA/TDB) or primed i.m.
(5/250/50 µg H56/DDA/TDB) and boosted twice i.pulmon. (10/125/25 or 10/250/50 or 10/500/100 µg H56/DDA/TDB) at 2 weeks interval with H56 adjuvanted with
different concentrations of CAF01 (DDA/TDB). Lung cells and the lung draining LNs (TLN + MLN) were examined for CD4+CD44+ T cells and IFN-γ, TNF-α, and
IL-17 cytokines by intracellular flow cytometry analysis after stimulation with H56, 2 weeks after the last booster immunization. (A) Gating strategy for quantification
and localization of lung-associated CD44+ T cells in immunized mice (exemplified by lung cells from an immunized mouse from the vaccine group 125/25
i.m./2*i.pulmon.). Lung cells were examined for labeling with i.v. injected FITC-conjugated anti-CD45.2 mAb 2 weeks after the last booster immunization by
intracellular flow cytometry analysis after stimulation with H56. Dot plot shows IFN-γ, TNF-α, or IL-17 expression in i.v.CD45+ (intravascular) and i.v.CD45−
(parenchymal) cells. (B) Number of cyt+CD4+CD44+ T cells (any cytokine IFN-γ, TNF-α, and IL-17), which are located in lung parenchyma (CD45−). Statistical
analysis: one-way ANOVA and Tukey’s post-test. Bars represent mean values ± s.e.m., n = 6. ****p < 0.0001. (C) After Boolean gating analysis, the frequencies of
the seven possible CD4+CD44+ T cell subpopulations expressing any combination of the IFN-γ, TNF-α, and IL-17 cytokines are shown for all immunization groups.
The background from the control group was subtracted. Pie charts represent the fraction of CD4+CD44+ T cells expressing different cytokine combinations. Pie chart
color-coding and the subpopulation association for each color is shown below the bar graph (E). Statistical analysis: two-way ANOVA and Tukey’s post-test. Bars
represent mean values ± s.e.m., n = 6. *p < 0.05, **p < 0.01, and ****p < 0.0001. (D) Number of cyt+CD4+CD44+ T cells (any cytokine IFN-γ, TNF-α, and IL-17) in
the lung draining LNs (TLN+MLN). Statistical analysis: one-way ANOVA and Tukey’s post-test. Bars represent mean values ± s.e.m., n = 6. **p < 0.01. (E) Boolean
gating analysis and pie charts of CD4+CD44+ T cells expressing different cytokine combinations in the lung-draining LNs (TLN+MLN), 2 weeks after the last booster
immunization. Statistical analysis: two-way ANOVA and Tukey’s post-test. Bars represent mean values ± s.e.m., n = 6. ****p < 0.0001.
generated equivalent frequencies of cytokine-producing
T cells as the 250/50 3∗i.m. immunization (Figure 6B).
When comparing the frequencies of CD4+CD44+ T cells
producing IFN-γ, TNF-α, and IL-17, respectively, we observed
that i.m./i.pulmon. immunization with 125/25 and 250/50
µg DDA/TDB stimulated equivalent frequencies of T
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cells as the i.m. immunization with 250/50 µg DDA/TDB
(Supplementary Figure S2C). Examination of the functionality
of the H56-specific CD4+CD44+ T in the spleen revealed
that i.m./i.pulmon. immunization with the lowest CAF01 dose
(125/25 µg DDA/TDB) induced primarily a polyfunctional
T cell population consisting of double (IFN-γ+TNF-α+ and
TNF-α+IL-17+) and triple (IFN-γ+TNF-α+IL-17+) positive,
cytokine-producing memory CD4+CD44+ T cells and TNF-α+
memory CD4+CD44+ T cells (Figure 6C, pies). Three i.m.
immunizations promoted a comparable functionality profile.
On the other hand, higher doses of CAF01 administered
i.m./i.pulmon. (250/50 and 500/100 µg DDA/TDB, respectively)
led to a dominant IFN-γ+TNF-α+ producing CD4+CD44+ T
cell population (Figure 6C, orange pies). Unlike for the lungs,
i.m./i.pulmon. immunization induced comparable frequencies
of H56-specific, cytokine-producing memory CD4+CD44+ T
cells in the spleen as the i.m./i.m. immunization (Figure 6C,
bars). i.m. and i.m./2∗i.pulmon. immunization with 125/25 µg
DDA/TDB also promoted similar frequencies of IFN-γ+ or
TNF-α+ producing effector CD4+CD44+ T cells.
Vaccine-induced T cells were also evaluated in the ILNs
and PLNs draining the site of i.m. injection (Figure 6A),
and we compared i.m./i.pulmon. vs. i.m./i.m. immunization,
respectively. The i.m./i.m. immunization with 250/50 µg
DDA/TDB induced higher but statistically indifferent
cytokine-producing frequencies of CD4+CD44+ T cells
in the draining LNs, as compared with i.m./i.pulmon.
immunization (Figure 6D). There was significant differences in
the frequencies of CD4+CD44+ T cells producing IFN-γ, TNF-
α, or IL-17 between the groups vaccinated by i.m./i.pulmon.,
as compared to i.m./i.m. immunization with 250/50 µg
DDA/TDB (Supplementary Figure S2D). However, there
was a considerable difference in the functionality of the
CD4+CD44+ T cells between the two immunization strategies
(Figure 6E, pies). Whereas i.m./i.pulmon. immunization
predominantly induced single cytokine-producing CD4+CD44+
T cells, i.m. immunization with 250/50 µg DDA/TDB resulted
in a polyfunctional T-cell population consisting of double
(IFN-γ+TNF-α+ and TNF-α+IL-17+) and triple (IFN-γ+TNF-
α
+IL-17+) positive, cytokine-producing memory CD4+CD44+
T cells and IFN-γ+ or TNF-α+ effector CD4+CD44+ T
cells. I.m./i.pulmon. immunization did mainly induce very low
frequencies of memory CD4+CD44+ T cells and promoted single
cytokine-producing effector CD4+CD44+ T cells (Figure 6E,
bars). The frequencies of memory and effector CD4+CD44+
T cells were significantly higher after i.m. immunization with
250/50 µg DDA/TDB, as compared to the frequencies detected
after i.m./i.pulmon. immunization.
The Biodistribution of Parenteral (s.c.)
Prime and Airway (i.pulmon.) Boost
Administered Vaccine Mimics the
Biodistribution of i.pulmon. Administered
Vaccine
We used SPECT/CT to investigate the biodistribution of
the H56/CAF01 vaccine following parenteral prime-airway
mucosal boost immunization and compared with our previous
biodistribution results. We performed this study as we wanted to
know whether there would be a faster clearance of H56 or CAF01
on i.pulmon. immunization with previously primed animals.
Mice were primed s.c. with cold H56 or cold H56/CAF01,
respectively, and boosted i.pulmon. 2 weeks later with 67Ga-H56
or 67Ga-H56/111In-CAF01, respectively. Mice were imaged by
SPECT/CT imaging at the designated time-points up to 144 h
post-injection, and the vaccine biodistribution was visualized
and quantified (Figure 7A and Supplementary Figure S3A),
followed by terminal ex vivo quantification of the biodistribution
on day 6 of the study. Dual-isotope labeling of H56 and
CAF01 with 111In and 67Ga, respectively, followed by SPECT-CT
imaging, allowed for anatomical visualization of vaccine uptake
in the lungs, as well as biodistribution and pharmacokinetics
(Figures 7B,C). The images demonstrate pronounced differences
in the biodistribution of H56 and CAF01 following s.c. prime
and i.pulmon. boost immunization, where H56 was cleared
within 24 h post-injection. The i.pulmon. administration of
unadjuvanted H56 resulted in a very fast clearance of H56
within 6 h (Supplementary Figure S3B). The vaccine remained
in the lungs for up to 6 h, followed by a slow redistribution to
the stomach and intestines up to 24 h of the study. The signal
from H56 was clearly visible until 24 h (Figure 7C) as compared
to CAF01, which could be weakly visualized up to 96 h post-
injection (Figure 7B). The in vivo quantification of radioactivity
in images through SUV values verify these findings (Figure 7D).
In contrast to a single i.pulmon. administration of the
H56/CAF01 vaccine, s.c. prime-i.pulmon. boost immunization
resulted in comparable activity of H56 and CAF01 in the
lungs at the designated time points (Figure 7D, upper left).
A relatively higher activity for both H56 and CAF01 was
observed in the trachea, kidneys and bladder within 30min
post-injection, which declined at later time-points. As observed
previously, a high activity of both H56 and CAF01 was observed
in the stomach and the intestines at 6 and 24 h post-injection.
The SUVs for unadjuvanted H56 showed a very low activity
in the lungs and other organs, and most of the activity
was observed in the kidneys within 6 h, which reflects that
immunization with unadjuvanted H56 leads to lower retention
in the lungs and faster metabolism and elimination of the
protein (Supplementary Figure S3C). Whole-body activity was
measured 144 h post-i.pulmon.-boost immunization. The results
are in line with the imaging-based in vivo biodistribution, and
the major fraction of the radioactivity was observed in the
lungs (Figure 7E). The biodistribution profile of unadjuvanted
H56 showed relatively low H56 activity in the lungs and
liver (Supplementary Figure S3D). For H56/CAF01 s.c. prime-
i.pulmon. boost immunization, there were differences in the
remaining activity ex vivo between H56 and CAF01 in the lungs
with comparatively higher radioactivity for H56 than for CAF01.
For all other organs than the lungs, a relatively low dose fraction
of CAF01-associated radioactivity was found in the liver, kidneys
and intestine, as observed previously following either a single
s.c. or i.pulmon. administration (Figure 7E). In contrast, H56
radioactivity was detectable in relatively higher dose fractions in
the liver and kidneys, which supports our prior observations of a
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FIGURE 6 | Parenteral (i.m.) prime and airway (i.pulmon.) mucosal boost immunization with H56/CAF01 induce equivalent T-cell responses in the spleen as parenteral
(i.m.) prime-boost immunization. Mice were primed i.m. and boosted twice i.m. (5/250/50 µg H56/DDA/TDB) or primed i.m. (5/250/50 µg H56/DDA/TDB) and
boosted twice i.pulmon. (10/125/25 or 10/250/50 or 10/500/100 µg H56/DDA/TDB) at 2 weeks interval with H56 adjuvanted with different concentrations of CAF01
(DDA/TDB). Spleen cells and the inguinal and popliteal lymph nodes (ILN+PLN) draining the site of i.m. injection were harvested 2 weeks after the last booster
immunization, surface-stained for the CD4 and CD44 receptors and intracellular localized IFN-γ, TNF-α, and IL-17 cytokines by intracellular flow cytometry analysis
after stimulation with H56. (A) Gating strategy for the evaluation of antigen-specific, cytokine-producing CD44+ T cells in spleen and lymph nodes of immunized mice
(exemplified by TLN + MLN cells from an immunized mouse from the vaccine group 125/25 i.m./2*i.pulmon.). Dot plot shows IFN-γ, TNF-α, or IL-17 expression in
CD44+ T cells. (B) Number of cyt+CD4+CD44+ T cells (any cytokine IFN-γ, TNF-α, and IL-17) in the spleen. Statistical analysis: one-way ANOVA and Tukey’s
post-test. Bars represent mean values ± s.e.m., n = 6. *p < 0.05. (C) After a Boolean gating analysis, the frequencies of the seven possible CD4+CD44+ T cell
subpopulations expressing any combination of the IFN-γ, TNF-α, and IL-17 cytokines are shown for all immunization groups. Background from the control group was
subtracted. Pie charts represent the fraction of CD4+CD44+ T cells expressing different cytokine combinations. Pie chart color-coding and the subpopulation
association for each color is shown below the bar graph (E). Statistical analysis: two-way ANOVA and Tukey’s post-test. Bars represent mean values ± s.e.m., n = 6.
*p < 0.05 and ****p < 0.0001. (D) Number of cyt+CD4+CD44+ T cells (any cytokine IFN-γ, TNF-α and IL-17) in LNs draining the site of injection (ILN + PLN). Bars
represent mean values ± s.e.m., n = 6. (E) Boolean gating analysis and pie charts of CD4+CD44+ T cells expressing different cytokine combinations in the LNs
draining the site of injection (ILN+PLN) 2 weeks after the last booster immunization. Statistical analysis: two-way ANOVA and Tukey’s post-test. Bars represent mean
values ± s.e.m., n = 6. *p < 0.05, **p < 0.01 and ****p < 0.0001.
faster clearance of H56 than CAF01 (Figure 7E). Proportionately
higher amounts of H56 activity was also observed in organs
other than the liver and the kidneys. However, no remaining
activity was detected in the lung-draining LNs, as observed
earlier. We also compared the activity of 67Ga-H56 alone with
67Ga-H56 adsorbed to 111In-CAF01 and observed significant
differences in the pulmonary uptake and biodistribution of
unadjuvanted protein, as compared to liposome-adsorbed
protein (Supplementary Figure S4). Unadjuvanted H56 was
cleared much faster than the CAF01-bound H56.
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FIGURE 7 | H56/CAF01 vaccine biodistribution upon parenteral (s.c.) priming and airway (i.pulmon.) mucosal boosting follow a similar trend as the biodistribution
following airway (i.pulmon.) mucosal prime immunization. (A) Experimental scheme: Mice were prime-immunized s.c. with 5 µg cold H56 adjuvanted with cold CAF01
(250/50 µg DDA/TDB). At week 2, animals were boost-immunized via intrapulmonary (i.pulmon.) route with 10 µg 67Ga-H56 adjuvanted with 111 In-CAF01 (125/25
µg DDA/TDB). Animals were imaged by dynamic whole-body SPECT/CT scan for the initial 40min (10 min/frame) and after that static 40min scans at 6 and 24 h,
60min scan at 96 h and 90min scan at 144 h were conducted. Animals were euthanized on day 6 after immunization for ex vivo biodistribution using a gamma
counter. Representative SPECT/CT images showing biodistribution of 111 In-CAF01 (B) and 67Ga-H56 (C) of a mouse prime-immunized s.c. with H56/CAF01 and
boost-immunized i.pulmon. with 67Ga-H56 + 111 In-CAF01. (D) Organ SUVs (g/mL) were calculated from dynamic and static SPECT/CT images of the cold s.c.
prime-immunized and hot (67Ga-H56 + 111 In-CAF01) i.pulmon. boost-immunized animals over 144 h post-immunization. Statistical analysis: two-way ANOVA and
Sidak’s post-test. Data represent mean values ± s.d., n = 3. **p < 0.01. (E) Ex vivo organ biodistribution [% administered dose (AD)/organ] of the cold s.c.
prime-immunized and hot (67Ga-H56 + 111 In-CAF01) i.pulmon. boost-immunized animals on day 6 (144 h) post-immunization. Statistical analysis: two-way ANOVA
and Sidak’s post-test. Bars represent mean values ± s.d., n = 3. *p < 0.05 and ****p < 0.0001.
DISCUSSION
Although a more efficacious vaccine is urgently needed for TB,
vaccine design and development has been very challenging due
to the specific requirement for induction of cell-mediated and
mucosal immunity (2). It is now widely accepted that it is
beneficial to stimulate Th1 and Th17 CD4+ T-cell responses
in the lungs for vaccine-induced protection in general (50,
51) and against Mtb infection in particular (52, 53). Mtb
evades host immunity by delaying the extravasation of primed
circulating antigen-specific T cells into the lung mucosa (2,
54). Antigen-specific T cells induced by parenteral vaccination
remain confined to tissue compartments outside of the lung
parenchyma and the airways, and are thus not capable of
mediating complete protection against Mtb (15, 55). Therefore,
a vaccination strategy, which induces and maintains tissue-
resident memory T cells and/or circulating T cells capable of
rapid influx into the lungs upon pathogen re-exposure, may
provide robust protection against Mtb infection. Parenteral
administration of the TB subunit vaccine H56/CAF01 has been
shown to induce promising protective efficacy in mice (29) and
non-human primates (30). However, the H56/CAF01 vaccine
has never been evaluated following airway (i.pulmon.) mucosal
immunization. Here, we document the immunogenicity of the
H56/CAF01 vaccine following parenteral (i.m.) priming and
airway (i.pulmon.) boost immunization, which induces local lung
and systemic memory CD4+ T cells and IgA responses. We
further describe, for the first time, the SPECT-CT imaging-based
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in vivo biodistribution and pharmacokinetics of the H56/CAF01
vaccine following parenteral (s.c.) or airway (i.pulmon.) priming
or parenteral prime-airway mucosal boost (s.c.- i.pulmon.)
immunization strategy. We observe pronounced differences in
the deposition, biodistribution and clearance of H56 protein
and CAF01 adjuvant. Our study provides new information on
H56/CAF01 mucosal boost immunization-inducible memory
CD4+ T cells in the lungs and SPECT/CT imaging-based in
vivo biodistribution of the individual vaccine components, which
may assist the development of effective mucosal immunization
strategies against pulmonary TB. These results also support
our ongoing efforts to develop a thermostable, dry powder-
based H56/CAF01 vaccine for i.pulmon. administration (43),
and we envisage the potential application of such an inhalable
dry powder dosage form in combination with a suitable device
for mass vaccination programs against TB. Hence, the safety of
airway mucosal vaccination has to be evaluated thoroughly in
future studies.
It is well-known that T cells play a crucial role in the
pulmonary host defense against many bacterial, viral, and fungal
pathogens, and inadequate T-cell immunity may increase the
likelihood of pathogen dissemination from the lungs (9). It is also
well-known that MHC class II-restricted CD4+ T cells producing
IFN-γ and TNF-α play important roles in protection against
TB in experimental animal models and in humans (56, 57). In
many preclinical TB challenge studies, increased CD4+ central
memory T cells have been associated with enhanced protection
(14, 57, 58). Localization of antigen-specific CD4+ T cells at the
site of infection in the lung parenchyma is of ultimate importance
for disease protection after vaccination (52, 56). However, Mtb
infection greatly interferes with migration of circulating vaccine-
induced antigen-specific T cells to the lungs (19), which is
correlated with lack of protection (15, 59). Therefore, novel
immunization strategies are needed to induce T cells that
effectively home back to the lung parenchyma in the airways.
In the present study, we introduce an effective immunization
protocol for the H56/CAF01 vaccine, which results in induction
of strong Th1, Th17, and IgA responses in the airways. We
show that Th1 and Th17 cells are induced systemically after
airway mucosal boost immunization of parenterally primed H56
antigen in a CAF01 dose-dependent manner, and that local lung
mucosal and systemic IgA and IgG responses accompany this.
We also show thatmucosal immunization induces polyfunctional
(IFN-γ+TNF-α+IL-17+) and double positive (IFN-γ+TNF-α+
and TNF-α+IL-17+) and TNF-α single-positive CD4+ T cells
in the lungs and the lung draining LNs (TLNs + MLNs) as
well as the spleen. The H56/CAF01 vaccine has previously
been shown to preferentially induce accumulation of TNF-
α single-positive, double positive (IFN-γ+TNF-α+ and TNF-
α
+IL-2+) and triple-positive (IFN-γ+TNF-α+IL-17+) CD4+ T
cells in the lungs, which provide protection against an Mtb
challenge (29). Our results also support previous observations
that less differentiated H56-specific T-cells have increased ability
to migrate into the lung parenchyma (39, 60). However, we also
observe CD4+ T cells with an intermediate state of differentiation
(IFN-γ+TNF-α+), as usually seen post-Mtb infection (39, 60,
61). The induction of this population following prime-boost
immunization could suggest that innate immune factors in the
lung microenvironment play an important role for the extent
of cell differentiation (62). However, the maintenance of an
IFN-γ+TNF-α+ double positive T-cell population has been
associated with enhanced control of mycobacterial growth (56,
57). Similarly, parenteral prime andmucosal boost immunization
were shown to induce strong mucosal and systemic immunity
(16, 63, 64), accompanied by improved protection in a number of
preclinical infectious disease models (65–67). Intranasal boosting
of parenterally primed immune responses was associated with
improved protection againstMtb infection, which correlated with
IFN-γ+ CD4+ and CD8+ T cells residing in the airway lumen
of the lungs (68). Similarly, respiratory mucosal boosting of
parenteral immunization resulted in improved protection against
Mtb infection, and it was accompanied by antigen-specific T
cell responses in the lungs (13, 69). Together with our data,
these findings suggest that parenteral prime and mucosal boost
immunization is a potentially effective strategy for inducing
lung-resident CD4+ T cells, which can subsequently provide an
improved protection against an Mtb challenge. We are currently
testing this strategy in anMtb challenge model.
Almost all licensed vaccines against infectious diseases
induce antibodies, which are correlated with disease protection
(70). Antibody-mediated protective immunity is mediated by
mucosal IgA, which prevents pathogen uptake across the
epithelial barrier, and by serum IgG, which prevents further
pathogen transmission via the blood (71). However, the role
of B cells and their production of antibodies in the immune
response to Mtb infection remains elusive (72–74). Recently,
there is growing evidence that Mtb-specific antibodies may
contribute to prevention of TB (75, 76), and one study reported
that antibodies recovered from healthcare workers provided
moderate protection against Mtb in mice (76). Furthermore,
a number of experimental studies have shown a protective
effect of antibodies against Mtb surface glycolipids (77, 78) and
recombinant antigens (79, 80). The induction of antigen-specific
IgA and IgG responses following prime-boost immunization in
our study strengthens these findings. Ideally, vaccine-induced
mucosal IgA antibodies present at the natural portal of entry
in the lungs, which are capable of fast neutralization of Mtb
following exposure, would be the optimal preventive strategy
against TB. In line with this, passive protection by mucosally
administered human IgA antibodies against Mtb infection in
the lungs of mice has been reported (81, 82). Recently, vaccine-
induced pulmonary secretory IgA has been associated with
immunological protection against TB in mice (17, 83). Given
the fact that antibodies are protective against many intracellular
infections, further studies are required to verify the functional
differences in antibodies to Mtb and the precise role of mucosal
antibodies in the immunological protection against TB (84).
In this study, we successfully radiolabeled CAF01 liposomes
with a lipophilic chelator, and developed an 111In-DTPA-CAF01
complex with high radiolabeling efficiency and purity. We also
describe the successful design of 111In-DTPA-H56 and 67Ga-
NOTA-H56 complexes, respectively, with high radiopurity and
radiolabeling efficiency. Radiolabeling of both H56 and CAF01
was not only easy and reproducible, but did also result in
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preserved size and integrity of both protein and liposomes.
The 111In and 67Ga radionuclides were selected due to their
relatively long half-life (111I n = 2.81 and 67Ga = 3.26 days),
their high photon energy, their ready and daily availability
as cyclotron-produced radionuclides, and the possibility for
clinical translation. Using SPECT-CT imaging, we confirmed
our previous studies showing that CAF01 forms a depot at
the site of injection (48). First, we show that 111In-CAF01
with surface-adsorbed cold H56 and 111In-H56 adsorbed onto
cold CAF01 remain at the site of injection for up to 6 days
post-s.c. injection, and we confirmed the observation through
ex vivo biodistribution. Using the tracer molecule 3H-DPPC
with DDA and TDB and 125I-labeled Ag85B-ESAT6 protein
(so-called H1), it was shown previously that CAF01 forms a
depot when injected i.m. or s.c. and promotes antigen retention
at the site of injection (48). Moreover, this depot effect was
correlated with the synchronization of DC uptake of antigen
and activation by CAF01, which is an important element for
the Th1/Th17 adjuvanticity of CAF01 (85, 86). However, in our
study, there was a clear difference in the biodistribution of H56
and CAF01 following s.c. injection; H56 was cleared faster than
CAF01 and was detected in the kidneys and the bladder already
6 h post-administration. Following pulmonary administration of
radiolabeled H56 and CAF01, respectively, we generally observed
rapid accumulation of radioactivity in the lungs and the bladder
within the first hour post-administration. The observed activity
in the trachea is caused by deposition of very small amounts
of activity from the tip of the MicroSprayer R© needle during
i.pulmon. administration. At later time-points, the amount of
radioactive H56 in the lungs, although lower, was detectable until
24 h, as compared to radioactive CAF01, which was observed
until 96 h. For both H56 and CAF01, radioactivity was observed
in the stomach and the intestines from 6 to 24 h post-injection,
which could be due to cough reflux during the withdrawal of
the MicroSprayer R© needle from the trachea, or clearance of
the dispersion from the trachea and subsequent swallowing, as
previously reported (47). Nevertheless, the applied i.pulmon.
administration method enables a rather uniform distribution
of the aerosolized vaccine into both lung lobes as observed
by SPECT imaging. This is further supported by the fact that
extrapulmonary distribution following aerosolization did not
influence the overall vaccine immunogenicity, and it was not
associated with any apparent side effects or systemic toxicity
during the study period (up to a maximum of 6 weeks).
Induction of cell-mediated immunity by vaccination is
challenging. It is believed that repeated administration of the
same vaccine (homologous boosting) is effective for increasing
humoral but not cellular immune responses, while heterologous
prime-boost immunization induces strong humoral and cellular
immune responses (87, 88). However, the use of the homologous
parenteral prime-mucosal boost immunization schedule has
been shown to induce simultaneous robust local mucosal and
systemic protective cellular and humoral immunity against
mucosal pathogens, e.g., Mtb and HIV (13, 63, 69). Our
data show that homologous parenteral priming followed by
airway boosting with H56/CAF01 elicits strong antigen-specific
CD4+ T cell responses, both in the spleen and the lungs,
and IgA responses in both serum and lungs, as compared to
parenteral homologous prime-boost immunizations. Recently,
it was reported that the administration route used for priming
and boosting of the H56/CAF01 vaccine is important for
improving and directing the vaccine-induced immune responses
using either the homologous or heterologous prime-boost
combinations (22). Largely, the enhanced immunity following
prime-boost homologous or heterologous immunization to the
target antigen is reflected predominantly by cellular events, e.g.,
an increased number of antigen-specific T cells, enrichment
of high-avidity T cells, and subsequent increased protective
efficacy against a pathogen challenge (89). Having demonstrated
significantly higher CD4+ T-cell- and antibody responses
for homologous prime-boost immunization, we evaluated the
biodistribution and pharmacokinetics of the H56/CAF01 vaccine
by SPECT/CT imaging to compare pulmonary uptake and
distribution between airway (i.pulmon.) prime vs. parenteral
(s.c.) prime—airway (i.pulmon.) mucosal boost immunization
strategies. However, the vaccine biodistribution in airway-
boosted animals that were primed s.c. with the homologous
vaccine was not significantly different from the biodistribution
in s.c.- primed only animals. Since most of the immunological
events are taking place at the cellular level initially in the
lung mucosa and draining lymph nodes followed by systemic
circulation, whole-body SPECT/CT imaging cannot be used
to differentiate the cellular events during prime vs. prime-
boost immunization. Nevertheless, the comparable vaccine
biodistribution profiles upon homologous prime and prime-
boost immunization underlines the reproducibility of our
radiolabeling results and emphasizes the usability of the
SPECT/CT imaging-based approach for quantification of the
biodistribution of subunit vaccines. Our novel data represent
dual-isotope radiolabeling and preclinical non-invasive and
longitudinal SPECT/CT imaging of the H56/CAF01 vaccine as
a readily translatable strategy, which can be integrated into a
clinical workflow. In addition, this novel radiolabeling platform
can be used to identify image-derived biomarkers, which could be
used to image vaccine-induced immune response, where imaging
of sites such as lungs, LNs and spleen can provide additional
information about vaccine-induced immune response as well
as safety and efficacy. Interestingly, a recent study reported
a PET imaging-derived biomarker that can be used to image
activated T cells to predict tumor responses to in situ vaccination
(90). Future studies should include devising novel immuno-
SPECT/CT strategies for the identification of H56/CAF01
vaccine-induced activated T cells for differentiating prime
vs. prime-boost immunizations and corresponding vaccine
efficacy.
From our data we can conclude that strong IgA antibody
and polyfunctional Th1 and Th17 cell responses are induced in
the lung mucosa and the systemic circulation upon parenteral
(i.m.) priming combined with airway (i.pulmon.) mucosal
boost immunization with the TB subunit vaccine H56/CAF01,
as compared to parenteral (i.m.) priming combined with
parenteral (i.m.) boost immunization. These data demonstrate
that parenteral priming followed by airway mucosal boosting
with the H56/CAF01 vaccine is a novel immunization strategy
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for improving vaccine immunogenicity and directing the
trafficking of antigen-specific CD4+ T cells to the lungs. These
results warrants further preclinical and clinical development of
H56/CAF01 as an inhalable and self-administrable aerosol
vaccine. We conclude that there are very pronounced
differences in the pharmacokinetics of H56 and CAF01
based on dual isotope (111In/67Ga)-based SPECT/CT imaging
of the vaccine biodistribution. Our results also suggest a
comparable biodistribution profile of the H56/CAF01 vaccine
following airway (i.pulmon.) prime and parenteral prime
(s.c.)—airway (i.pulmon.) mucosal boost immunization,
respectively. We believe that immuno-SPECT/CT strategies
can be developed, based on this novel radiolabeling platform,
for imaging of H56/CAF01 vaccine-induced activated T
cells at specific effector sites, e.g., the lungs. Overall, our
findings may hold considerable implications for the rational
design of effective mucosal immunization strategies against
TB.
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